The Green Cross Corporation

Yoshio Kagitani

Yasuo Ueda

Tadakazu Suyama

Satoshi Funakoshi

Nobuhiko Komatsu

Daisuke Satoh

Kenji Tanaka

Kazumasa Yokoyama

Yoshio Arakawa

Yusei Shiraga

Atuyuki Takanabe

Satoshi Morimoto

Shirou Komeda

Takao Ohmura

Masayuki Nishida

Ryozo Watanabe

Tsunekazu Fukushima

Takashi Imagawa

Hirohisa Inahara

Eiji Sako

Tunetaka Nakajima

Takuji Doi

Kozi Munechika

Hiroshi Emoto

An alkali metal hydrogensulfite or sulfite is effective for controlling a local injury such as inflammation and vein injury occurring on the injection of an antitumor benzodiazepine compound of the formula ##STR1## wherein R.sub.1 denotes hydrogen atom, or acyl, carbamyl, or alkoxycarbonyl group; R.sub.2 denotes hydrogen atom or acyl group; and R.sub.3 denotes sulfinic acid rest, SO.sub.2 X, or sulfonic acid rest, SO.sub.3 X, X meaning hydrogen, alkali metal or alkaline earth metal. An aqueous solution containing the both can be administered by injection.

Injectable aqueous solution containing hydrogensulfite and/or sulfite

The invention provides a method of producing a water-soluble complex comprising a water-insoluble drug and a phospholipid, comprising the steps of (1) dissolving a water-insoluble drug and a phospholipid in an organic solvent, (2) removing the solvent to leave behind a drug-containing phospholipid film, (3) suspending the resulting film in an aqueous solution, (4) ultrasonicating the film, (5) centrifuging the resulting suspension, and (6) recovering the lowermost layer of the resulting sediment to yield the water-soluble complex. The above complex can be administered parenterally as well as by the oral and other routes, and is so rich in the drug component that a remarkably increased drug activity can be realized.

Water soluble drug complex and method for production of same

Benzodiazepine derivative represented by the following general formula or pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 is --COR.sup.4 (R.sup.4 is a carboxylic acid residue) or an alkyl or aralkyl group (these groups have a substituent selected from a carboxyl group, an amino group and a cyano group), R.sup.2 is a lower alkyl group and R.sup.3 is a hydrogen atom or a lower alkyl group. The above compound is low in toxicity and has an antitumor activity.

1H-pyrrolo-[2,1-C][1,4]benzodiazepine-2-acrylamide compounds having

The drug such as antitumor agents or antibiotics can preferentially be carried to a morbid part, for example, injured tissue and tumor site by administering its complex with fibronectin combined through an oxidized dextran to repair the morbid part. The complex is prepared by reacting the drug, an oxidized dextran having a cleaved structure of aldohexopyranose ring, and fibronectin.

Fibronectin-dextran-drug complex and method of preparation thereof

Physiologically active substances such as antibiotics can preferentially be carried to a morbid part, for example, injured tissue and neoplastic cell proliferation site by administering its complex with fibronectin to repair the morbid part. The complex is prepared by the reaction between the physiologically active substance and the fibronectin with or without intervention of a protein cross-linking agent.

Fibronectin-physiologically active substance complex and method of

Novel 5,10,11,11a-tetrahydro-8-methyl-11-sulfo or sulfino-1H-pyrrolo[2,1-c][1,4]-benzodiazepin-2-acrylamides which have antitumor activity and low toxicity are prepared by reacting corresponding 11-reactive compound with a reactive sulfur compound to form 11-sulfino compounds and, if desired, oxidizing the 11-sulfino compounds to obtain 11-sulfo compound.

Pyrrolo-benzodiazepine compounds and anti-tumor composition thereof

Acetylsalicylates with basic amino acids such as DL-lysine is stabilized in the form of solid preparation by admixing anhydrous calcium chloride therewith. The preparation containing calcium chloride is prevented from hydrolysis and can be stored for a long period of time even at a relatively high room temperature. The preparation is further prevented from discarolation when glycine is added thereto.

Acetylsalicylate powder preparation for injection

Novel perhydro-1H-pyrrolo[2,1-C][1,4]benzodiazepin-5-one compounds having antitumor activity, perhydro-1H-pyrrolo[2,1-C][1,4]-benzodiazepin-5,11-dione, compounds which are synthetic intermediate of the former, and processes for producing these compounds.

Pyrrolo benzodiazepine compounds

Novel perhydro-1H-pyrrolo[2,1-C][1,4]benzodiazepin-5-one compounds having antitumor activity, perhydro-1H-pyrrolo[2,1-C][1,4]-benzodiazepin-5,11-dione compounds which are synthetic intermediate of the former, and processes for producing these compounds.

Growing community of inventors

Kashihara, Japan

Yoshio Kagitani